Physician profile
Kenneth W Roach
NPI 1780686014
$2,128.42
in general payments reported to CMS, 2019-2025
13 companies · $552 in 2025
The $552 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $140 · 2020: $53.18 · 2021: $319 · 2022: $445 · 2023: $358 · 2024: $261 · 2025: $552.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,170.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,153.04 | 2021-2025 | Rocklatan, Clareon Panoptix Pro, Rhopressa |
| Bausch & Lomb Americas INC. | $301.67 | 2022-2025 | Vyzulta, Xiidra, Miebo |
| Allergan, INC. | $200.55 | 2019-2022 | |
| Ocular Therapeutix, INC. | $88.80 | 2019 | |
| Novartis Pharmaceuticals Corporation | $83.71 | 2021-2023 | |
| Sun Pharmaceutical Industries INC. | $66.36 | 2021-2024 | |
| Abbvie INC. | $58.71 | 2023 | Durysta, Xen Glaucoma Treatment System |
| Mallinckrodt Hospital Products INC. | $47.82 | 2022 | |
| Oyster Point Pharma, INC. | $38.83 | 2022-2023 | Tyrvaya |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $31.21 | 2020-2021 | |
| Glaukos Corporation | $23.10 | 2020 | |
| Ivantis, INC | $18.42 | 2020 | |
| New World Medical,INC. | $16.20 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Roach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.